Although the incidence of IDH1/2 mutations is only 0.4%‐1.1% in NSCLCs, it is worthwhile to investigate IDH1/2 inhibitors because of the high prevalence of lung cancers in the United States and worldwide. Here, IDH1 is linked to lung carcinoma.